• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Exclusives
    • Nutraceuticals
    • Markets
    • Health
    • Jobs
    • Events
    • Buyers' Guide
    • Showcases
    • More
  • Magazine
  • News
  • Exclusives
  • Nutraceuticals
  • Markets
  • Health
  • Jobs
  • Events
  • Buyers' Guide
  • Showcases
  • Current & Past Issues
    Features
    Columns
    Editorials
    Digital Edition
    Subscribe Now
    Advertise Now
    eNewsletter
    Editorial Guidelines
    Top Features
    Contract Manufacturing: Trials & Tribulations of Today’s Supply Chains

    Analytical Testing in Nutraceuticals: Methods and Mindsets to Uphold Quality

    Nutrition and Flavor: Formulating for Modern Product Preferences

    What Do Consumers Know About the Gut Microbiome?

    How Will the European Green Deal Impact Dietary Supplements?
    Breaking News
    Certifications, Approvals and Patents
    Exclusives
    Industry & Market News
    People
    Products
    Regulatory
    Research
    Supplier News
    Supplier Insights
    Live From Shows
    Top News
    Flower Pollen Extract Benefits Women’s Urinary Incontinence, Study Finds

    3i Solutions Announces New Leadership Positions

    INS Nutra Opens Gummy Manufacturing Facility

    Vital Nutrients Launches First Vegan Omega Supplement with SPMs

    Earth Mama Organics Achieves 'Plastic Neutral' Certification
    Exclusives
    Blogs & Guest Articles
    Health E-Insights
    Area Code 420
    eBook
    Antioxidants
    Dairy-Based Ingredients
    Enzymes
    Fatty Acids
    Fiber & Carbohydrates
    Green Foods
    Herbs & Botanicals
    Marine Nutraceuticals
    Minerals
    Omega 3s
    Probiotics & Prebiotics
    Proteins, Peptides, Amino Acids
    Sweeteners
    Vitamins

    Flower Pollen Extract Benefits Women’s Urinary Incontinence, Study Finds

    Vital Nutrients Launches First Vegan Omega Supplement with SPMs

    Bill Chioffi Joins Nammex as Chief Strategy and Innovation Officer

    FDA Issues ‘No Questions’ Letter for Chiber Mushroom Fiber Preservative

    VITAL Ancillary Study Finds No Link Between Vitamin D and Bone Fracture Risk
    Consumer Trends
    Contract Manufacturing
    Cosmeceuticals / Nutricosmetics
    Delivery & Dosage Technologies
    Dietary Supplements
    Flavors & Colors
    Functional Foods & Beverages
    Healthcare Trends
    Medical Nutrition
    Mergers & Acquisitions
    Natural/Organic
    Nutrition Bars
    Packaging
    Pet Nutraceuticals
    Quality & Safety
    Regulations
    Research
    Testing
    World Markets

    Flower Pollen Extract Benefits Women’s Urinary Incontinence, Study Finds

    3i Solutions Announces New Leadership Positions

    INS Nutra Opens Gummy Manufacturing Facility

    Vital Nutrients Launches First Vegan Omega Supplement with SPMs

    Earth Mama Organics Achieves 'Plastic Neutral' Certification
    Bone & Joint Health
    Cancer Risk
    Cardiovascular Health
    Cognitive Function
    Diabetes & Blood Sugar Management
    Digestive Health
    Energy
    Eye Health
    Healthy Aging
    Immune Function
    Infant & Children's Health
    Inflammation
    Men's Health
    Mood Health & Sleep
    Oral Health
    Sexual & Reproductive Health
    Skin Health
    Sports Nutrition
    Weight Management/Weight Loss
    Women's Health

    Flower Pollen Extract Benefits Women’s Urinary Incontinence, Study Finds

    Vital Nutrients Launches First Vegan Omega Supplement with SPMs

    VITAL Ancillary Study Finds No Link Between Vitamin D and Bone Fracture Risk

    Krill Oil Study Provides Evidence of Osteoarthritis Benefits

    Immunobiotic Heat-Killed Bacteria Linked to Skin Benefits
    Industry Events
    Live From Show Events
    Webinars
    All Companies
    Categories
    Trade Associations
    Company Capabilities
    International Buyers Guide Companies
    BGG World

    Xsto Solutions

    Atlantia Clinical Trials

    Botanic Healthcare LLC

    Verdure Sciences
    Companies
    Product Releases
    News Releases
    Literature / Brochures
    White Papers
    Jobs
    VIdeos
    Services
    Add New Company
    International Buyers Guide Companies
    BGG World

    Xsto Solutions

    Atlantia Clinical Trials

    Botanic Healthcare LLC

    Verdure Sciences
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Digital Edition
      • eNewsletter Archive
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
    • Breaking News
    • Buyers' Guide
      • All Companies
      • Categories
      • Trade Associations
      • Company Capabilities
    • Nutraceuticals
      • Antioxidants
      • Dairy-Based Ingredients
      • Enzymes
      • Fatty Acids
      • Fiber & Carbohydrates
      • Green Foods
      • Herbs & Botanicals
      • Marine Nutraceuticals
      • Minerals
      • Omega 3s
      • Probiotics & Prebiotics
      • Proteins, Peptides, Amino Acids
      • Sweeteners
      • Vitamins
    • Markets
      • Consumer Trends
      • Contract Manufacturing
      • Cosmeceuticals / Nutricosmetics
      • Delivery & Dosage Technologies
      • Dietary Supplements
      • Flavors & Colors
      • Functional Foods & Beverages
      • Healthcare Trends
      • Medical Nutrition
      • Mergers & Acquisitions
      • Natural/Organic
      • Nutrition Bars
      • Packaging
      • Pet Nutraceuticals
      • Quality & Safety
      • Regulations
      • Research
      • Testing
      • World Markets
    • Health
      • Bone & Joint Health
      • Cancer Risk
      • Cardiovascular Health
      • Cognitive Function
      • Diabetes & Blood Sugar Management
      • Digestive Health
      • Energy
      • Eye Health
      • Healthy Aging
      • Immune Function
      • Infant & Children's Health
      • Inflammation
      • Men's Health
      • Mood Health & Sleep
      • Oral Health
      • Sexual & Reproductive Health
      • Skin Health
      • Sports Nutrition
      • Weight Management/Weight Loss
      • Women's Health
    • Online Exclusives
    • Webinars
    • Slideshows
    • Blogs & Guest Articles
    • Health E-Insights
    • Videos
    • Podcasts
    • Infographics
    • eBook
    • Whitepapers
    • Research
      • TrendSense
      • Monograph Center
      • White Papers
      • Research News
    • Jobs
    • Events
      • Industry Events
      • Live From Show Events
      • Webinars
    • Supplier Showcases
      • Companies
      • Product Releases
      • News Releases
      • Literature / Brochures
      • White Papers
      • Jobs
      • VIdeos
      • Services
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    Demystifying the Regulatory Status of CBD

    The hype and the legal issues surrounding cannabinoids need context, and you probably need a lawyer.

    Demystifying the Regulatory Status of CBD
    Related CONTENT
    • What People Were Reading in July 2022 on NutraceuticalsWorld.com
    • Largest Cannabinoids Trial to Date Yields Positive Findings on Pain Management
    • Senate HELP Committee Advances Bill with Supplement Provisions That Industry Trade Groups Oppose
    • Kemin Launches Luxiva Hemp CBD Distillates
    • EFSA: Data Too Limited To Evaluate CBD as Novel Food Ingredient
    By Todd Harrison, Venable11.01.18
    With the explosion of interest in products that contain cannabidiol (CBD), now seems like the perfect time to discuss the regulatory status of cannabinoids. This column does not take a position on whether CBD or other cannabinoids should be permitted, from a policy perspective, to be marketed over-the-counter as dietary supplements. Rather, I am posing a series of questions intended to assist companies in determining whether it’s worth the business risk to market these products. So, here we go...

    Question 1: What laws control the use of CBD in dietary supplements?

    Answer: The Control Substance Act (CSA), The Federal Food, Drug, and Cosmetic Act (the Act), the Farm Act of 2014, and finally state laws. Understand, state laws that permit the marketing of CBD products may only pertain to products cultivated, grown. and manufactured within the state pursuant to a permit or license issued by the state. Put another way, a state may prohibit the sale of CBD and hemp extracts that are produced in other states.

    Question 2: Are CBD and other cannabinoids Schedule I controlled substances?

    Answer: The answer to this question turns on the definition of marijuana and whether it is an FDA-approved drug. More specifically, only CBD and cannabinoids that come from the non-resin portion of the plant, including the stalk and the seeds, are exempt from the definition of marijuana and therefore are not Schedule I controlled substances. FDA-approved drugs are Schedule V controlled substances. 

    Question 3: Doesn’t the Farm Act of 2014 essentially de-schedule hemp? 

    Answer: No, it does not. Indeed, the Farm Act of 2014 only permits the growing and propagation of hemp as part of a research project within a state. Even if one could argue that limited commercialization within a state permits the marketing of CBD dietary supplements, it would only apply to that state. For instance, you could not market a CBD dietary supplement that is from the flower or leaf of the plant in the state of Maryland unless the hemp was grown in Maryland pursuant to a permit issued by the state of Maryland. For some reason, this fact remains lost on the industry. Also, if it did allow for the interstate commercialization of hemp and hemp-derived products, the proposed language in the Farm Bill of 2018 de-scheduling hemp would be unnecessary. 

    Question 4: If the CBD in a product comes from the stalk or seed of hemp, can I market it as a dietary supplement or as an ingredient in food?

    Answer: I am not going to be drawn into a debate as to whether it is economically feasible to extract CBD from the stalk or seed of hemp. For our purposes here, we will presume that this statement is true. However, the only practical legal impact is that the product is not subject to the CSA. Similarly, if the source of CBD or other cannabinoids do not come from hemp or other cannabis cultivars, then it is not subject to the CSA.

    However, one must also analyze it under the Federal Food, Drug, and Cosmetic Act. Under Section 201(ff)(3)(B), if the article is marketed as a dietary supplement, it must have been on the marketplace before FDA authorized its investigation as a new drug and substantial clinical trials have been undertaken. This means that CBD and other cannabinoids had to have been marketed prior to GW Pharmaceuticals’ IND for Epidiolex and the start of the clinical trials, which happened in 2007. FDA is on the record in numerous warning letters that it is unaware of CBD’s use in a dietary supplement prior to the IND and institution of clinical trials. 

    Similarly, Section 301(ll) of the Act, does not permit its addition into food if it was not marketed as an article in food prior to the institution of substantial clinical trials. Thus, a Generally Recognized As Safe (GRAS) document produced 11 years after the fact has no legal weight if it cannot be established that CBD was marketed prior to the clinical trials. 

    With that said, Section 301(ll)(2) does allow a company or industry to petition FDA to permit its use in food; so the door is open. The question is whether the industry wants to attempt to petition the agency to permit its marketing in food, which by default would also include dietary supplements. 

    It is important to note the article that was authorized for investigation and subsequent clinical trials is CBD. Cannabidiolic acid (CBDA) and other cannabinoids have not been authorized for investigation or subject to clinical trials. Thus, there is an opening here to market CBDA and the other cannabinoids once the controlled substance issue is straightened out.

    Finally, there are defenses to the preclusion provisions, however, you will need to seek the advice of legal counsel to determine how strong these arguments are, as I do not have the space in this column to go through all the legal arguments. Some of them have merit and pass the laugh test while others are highly suspect. Regardless, this requires you to work through counsel to determine the strength of those arguments. 

    Question 5: Everyone is marketing CBD so it must be legal, right?

    Answer: Law enforcement and regulatory agencies routinely permit the marketing of products that may otherwise be violative through enforcement discretion. Here, I agree, the DEA does not seem very interested and FDA simply needs to make a decision to permit its marketing or enforce. However, while it is high enough on its priority list to merit warning letters, it is not so high (pun intended) to warrant enforcement action, but that is simply reading the tea leaves. 

    With that said, here is something that no one talks about and people refuse to deal with: domestic credit card processors will not knowingly process for companies that are selling CBD because of concerns regarding its controlled substance status. Thus, many of the companies that are processing are not informing the processor that it is for CBD products, which may itself create an entirely different set of legal issues; or they are using expensive offshore processors, which come at a premium. Of course, this is another issue that is simply not discussed but must be factored into any decision to market CBD products.

    Question 6: When the Farm Bill of 2018 is passed won’t it take care of everything?

    Answer: By the time this column publishes, the Farm Bill of 2018 may have passed and it may include language about hemp. However, the Farm Bill of 2018 only de-schedules hemp and products derived from hemp; it does not impact the FFDCA analysis because the language (as it stands as of this writing) makes it clear that nothing within the bill would modify or preempt the FFDCA.

    Question 7: What about topical products?

    Answer: Presuming you can overcome the CSA, the preclusion provisions of the FFDCA do not apply to topical cosmetic products as along as impermissible drug claims are not being made. 
    I hope this column at least places the issues surrounding CBD and cannabinoids in the appropriate context. I am hopeful that in the near future the CSA issue will be placed to rest with the Farm Bill of 2018. I am also hopeful that at some point someone with strong safety data comes forward to request permission from FDA to sell CBD in foods and dietary supplements, as there is a reason we have an endocannabinoid system. Providing it with nutritional support would have significant health benefits completely unrelated to treating rare epileptic seizures.

    As I have stated so many times in columns and speeches, we need to stop treating everything as a binary choice between being diseased or being healthy. In fact, “healthy” encompasses a wide spectrum. Indeed, osteoarthritis, while classified as a disease, is in fact normal wear and tear that we all experience. Yet people are denied access to products that may help them and instead are prescribed opioids; and we have seen what that has wrought on society.

    Companies in the natural product/dietary supplement industry often wonder why regulators don’t seem to trust the industry. However, rushing ingredients into the market on questionable legal theories without following the regulatory process is one reason for this distrust. I understand frustration when it comes to claims, but cavalier attitudes toward regulatory procedures of ingredients pose a more long-term threat to the industry.

    Still, it’s challenging when FDA seems more concerned with “disease” claims related to supporting fertility and age-related joint pain rather than enforcing the dietary ingredient provisions of the Act. But that is simply my take about ingredients in general, and not on CBD in particular.


    Todd Harrison
    Venable

    Todd Harrison is partner with Venable, which is located in Washington, D.C. He advises food and drug companies on a variety of FDA and FTC matters, with an emphasis on dietary supplement, functional food, biotech, legislative, adulteration, labeling, and advertising issues. He can be reached at 575 7th St. NW, Washington, D.C. 20004, Tel: 202-344-4724; E-mail: taharrison@venable.com.
    Related Searches
    • Health
    • Natural
    • ftc
    • Adulteration
    Suggested For You
    What People Were Reading in July 2022 on NutraceuticalsWorld.com What People Were Reading in July 2022 on NutraceuticalsWorld.com
    Largest Cannabinoids Trial to Date Yields Positive Findings on Pain Management Largest Cannabinoids Trial to Date Yields Positive Findings on Pain Management
    Senate HELP Committee Advances Bill with Supplement Provisions That Industry Trade Groups Oppose Senate HELP Committee Advances Bill with Supplement Provisions That Industry Trade Groups Oppose
    Kemin Launches Luxiva Hemp CBD Distillates Kemin Launches Luxiva Hemp CBD Distillates
    EFSA: Data Too Limited To Evaluate CBD as Novel Food Ingredient EFSA: Data Too Limited To Evaluate CBD as Novel Food Ingredient
    Tapping Functional Beverages to Meet Modern Wellness Needs Tapping Functional Beverages to Meet Modern Wellness Needs
    What People Were Reading in May 2022 on NutraceuticalsWorld.com What People Were Reading in May 2022 on NutraceuticalsWorld.com
    FDA Issues Draft Guidance on NDI Enforcement Discretion FDA Issues Draft Guidance on NDI Enforcement Discretion
    Jordan Process Receives Nutrasource ICAP Certification for CBD Jordan Process Receives Nutrasource ICAP Certification for CBD
    Draft Senate Bill to Reauthorize FDA User Fees Includes Dietary Supplement Listing Provision Draft Senate Bill to Reauthorize FDA User Fees Includes Dietary Supplement Listing Provision
    Open Book Extracts Completes Phase 1 of Toxicology, Safety Assessment for Cannabinoid Ingredients Open Book Extracts Completes Phase 1 of Toxicology, Safety Assessment for Cannabinoid Ingredients
    FDA Issues Warning Letters to Companies Selling CBD, Delta-8 THC Products FDA Issues Warning Letters to Companies Selling CBD, Delta-8 THC Products
    HP Ingredients and H&AD to Showcase Ingredients at Vitafoods Europe HP Ingredients and H&AD to Showcase Ingredients at Vitafoods Europe
    Environmental, Social and Governance in the Cannabis Industry: A Perfect Storm is Brewing Environmental, Social and Governance in the Cannabis Industry: A Perfect Storm is Brewing
    James Roza of Layn Natural Ingredients: Driving the Science and Botanical Innovation James Roza of Layn Natural Ingredients: Driving the Science and Botanical Innovation

    Related Online Exclusives

    • Dietary Supplements
      What People Were Reading in July 2022 on NutraceuticalsWorld.com

      What People Were Reading in July 2022 on NutraceuticalsWorld.com

      These were the most viewed stories in July.
      08.02.22

    • Breaking News | Herbs & Botanicals | Medical Nutrition | Research | Research News
      Largest Cannabinoids Trial to Date Yields Positive Findings on Pain Management

      Largest Cannabinoids Trial to Date Yields Positive Findings on Pain Management

      Over 1,600 people with pain were randomized to take one of six cannabinoid formulations containing CBD and some combination of rare cannabinoids from OBX.
      07.05.22

    • Dietary Supplements | Regulations
      Senate HELP Committee Advances Bill with Supplement Provisions That Industry Trade Groups Oppose

      Senate HELP Committee Advances Bill with Supplement Provisions That Industry Trade Groups Oppose

      Wide-ranging ‘must-pass’ legislation heads to the full Senate for consideration.
      By Mike Montemarano, Associate Editor 06.17.22


    • Breaking News | Herbs & Botanicals | Supplier News
      Kemin Launches Luxiva Hemp CBD Distillates

      Kemin Launches Luxiva Hemp CBD Distillates

      The ingredient supplier expanded its hemp portfolio with a line of organic distillates at varying potencies.
      06.15.22

    • Breaking News | Herbs & Botanicals | Quality & Safety | Regulatory News | Research | World Markets
      EFSA: Data Too Limited To Evaluate CBD as Novel Food Ingredient

      EFSA: Data Too Limited To Evaluate CBD as Novel Food Ingredient

      In a statement issued by Europe’s foremost food safety authority, several data gaps on the safety of CBD were noted.
      06.08.22

    Loading, Please Wait..
    Trending
    • Pycnogenol Evidenced To Have Skin Benefits In Dermatology Study
    • Oregon Files Lawsuit Against GNC
    • Study Examines Vitamin K2 Content In Cheese
    • Study On Fortigel Collagen Peptides Suggests Knee Joint Discomfort Benefits
    • Vitamin K2 Status May Impact Blood Pressure And Pulse Wave Velocity
    Breaking News
    • Flower Pollen Extract Benefits Women’s Urinary Incontinence, Study Finds
    • 3i Solutions Announces New Leadership Positions
    • INS Nutra Opens Gummy Manufacturing Facility
    • Vital Nutrients Launches First Vegan Omega Supplement with SPMs
    • Earth Mama Organics Achieves 'Plastic Neutral' Certification
    View Breaking News >
    CURRENT ISSUE

    July/August 2022

    • A Growing Herbal Products Market Still Faces Formidable Threats, Challenges
    • Analytical Testing in Nutraceuticals: Methods and Mindsets to Uphold Quality
    • Nutrition and Flavor: Formulating for Modern Product Preferences
    • Contract Manufacturing: Trials & Tribulations of Today’s Supply Chains
    • How Will the European Green Deal Impact Dietary Supplements?
    • What Do Consumers Know About the Gut Microbiome?
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Flower Pollen Extract Benefits Women’s Urinary Incontinence, Study Finds
    3i Solutions Announces New Leadership Positions
    INS Nutra Opens Gummy Manufacturing Facility
    Coatings World

    Latest Breaking News From Coatings World

    Lanxess' Entire Value Chain to Become Climate-Neutral
    Custom Cars Featuring PPG DELTRON Refinish System Take Awards at Goodguys 24th Summit
    HGTV Home by Sherwin-Williams Announces 2023 Color Collection of the Year
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Endologix's AFX2 Endovascular AAA System Earns EU Nod
    Elizabeth Coleon Joins Withings as Chief Marketing Officer
    U.K. Strengthens Medical Device Regulations
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Pfizer to Acquire Global Blood Therapeutics for $5.4B
    BioIVT Acquires Scottish Drug-metabolizing Enzyme Manufacturer Cypex
    Schott Creates Stand-Alone Company for its Pharma Business
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Batiste Kicks Off Partnership with Fitness Brand
    The Body Shop Expands Partnership with Uber
    COSRX Launches Vitamin E Vitalizing Sunscreen
    Happi

    Latest Breaking News From Happi

    Hallstar To Purchase Lanxess’ Polymer Additives Production Site in Greensboro, NC
    Uber and The Body Shop Expand On-Demand Delivery Partnership Nationwide
    Australia-Based Teeth Whitening Technology Leader White Glo Enters US Market
    Ink World

    Latest Breaking News From Ink World

    Xerox Board of Directors Names Steven Bandrowczak as CEO
    ALTANA AG to Sell Its Stake in dp polar to 3D Systems
    Weekly Recap: Zeller+Gmelin, Epple Druckfarben Lead This Week’s News Stories
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Eukalin acquires Adhesives Specialists
    EyeC unveils new inspection products
    Errol Moebius named VP of IST America
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Weekly Recap: A New Day for Hygiene, Glatfelter Reports Q2 Results & More
    Dyper Achieves B Corp Certification
    Edgewell’s Sales Grow
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    OSSIO Rolls Out OSSIOfiber Suture Anchors in U.S.
    MicroPort Navibot’s SkyWalker System Cleared by FDA
    NuVasive Inc. Reports Q2 2022 Financial Results
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    CdTe Accelerator Consortium Aims to Reduce Costs, Speed Deployment
    Universal Display Announces Retirement Plans of CFO Sidney D. Rosenblatt
    Fast Company Names Zebra Technologies to 2022 Best Workplaces for Innovators

    Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login